Researchers conducted this study to evaluate the impact of flavonoids and cannabinoids as anti-inflammatory and antiallergic treatments on the eye’s anterior surface.

Allergic conjunctivitis and dry eye syndrome are common ocular surface diseases treated with traditional pharmacological measures, e.g. corticosteroids and antihistamines. Given the side-effect profiles of these medications and the growing interest in complementary treatment modalities as part of integrative medical interventions, well-known flavonoids, such as quercetin and catechin, are under investigation for topical and systemic application methods for relief. As flavonoid derivatives, pycnogenol and epigallocatechin gallate have alleviated dry eye symptoms, including lacrimal gland inflammation, tear secretion, and tear film stability. Research on visual cannabinoid receptors and response to synthetic cannabinoids is also considered for anterior ocular disorders. The expansion of herbal formulations provides a framework for future treatment regimens for visual surface disorders.

Flavonoids and cannabinoids show promise as a potential complementary treatment for allergic diseases because of their anti-inflammatory and antiallergic properties. Several studies implementing the ocular and systemic application of these compounds show potential in becoming adjuvant treatment strategies for improving quality of life while also managing visual ocular surface disease processes.

Reference: https://journals.lww.com/co-allergy/Abstract/2020/10000/Flavonoid_and_cannabinoid_impact_on_the_ocular.11.aspx

Author